HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Stocks News ETF News Crypto News

BioCryst Pharmaceuticals, Inc.

Contributing Author

Recent Articles by BioCryst Pharmaceuticals, Inc.

8 hours
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting BCRX GlobeNewswire
Oct-20
BioCryst to Report Third Quarter 2025 Financial Results on November 3 BCRX GlobeNewswire
Oct-14
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile BCRX GlobeNewswire
Oct-03
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Oct-01
BioCryst Completes Sale of European ORLADEYO (berotralstat) Business BCRX GlobeNewswire
Sep-03
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Aug-21
BioCryst to Present at Upcoming Investor Conference BCRX GlobeNewswire
Aug-11
BioCryst Announces Departure of Dr. Helen Thackray BCRX GlobeNewswire
Aug-06
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Aug-04
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
Jul-31
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December BCRX GlobeNewswire
Jul-21
BioCryst to Report Second Quarter 2025 Financial Results on August 4 BCRX GlobeNewswire
Jul-09
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit BCRX GlobeNewswire
Jul-07
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development BCRX GlobeNewswire
Jul-03
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Jun-27
BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million BCRX GlobeNewswire
Jun-16
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO (berotralstat) Across all Ages at EAACI BCRX GlobeNewswire
Jun-13
ORLADEYO (berotralstat) Approved in Colombia BCRX GlobeNewswire
Jun-06
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries BCRX GlobeNewswire
Jun-03
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Jun-02
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology BCRX GlobeNewswire
May-30
BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages BCRX GlobeNewswire
May-27
BioCryst to Present at Upcoming Investor Conferences BCRX GlobeNewswire
May-16
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) BCRX GlobeNewswire
May-14
BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years BCRX GlobeNewswire
May-05
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
May-02
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.